| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 09/07/2001 | WO2001064691A1 Il-8 receptor antagonists |
| 09/07/2001 | WO2001064681A2 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors |
| 09/07/2001 | WO2001064679A1 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
| 09/07/2001 | WO2001064677A1 Novel imidazotriazinones and the use thereof |
| 09/07/2001 | WO2001064672A1 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylat and polymorphs |
| 09/07/2001 | WO2001064671A2 Haloimidazole derivatives and their use as muscarinic m3 and serotoninergic 5-ht4 receptors |
| 09/07/2001 | WO2001064669A1 Pyrazole ether derivatives as anti-inflammatory/analgesic agents |
| 09/07/2001 | WO2001064668A2 1,3-dihydro-2h-indol-2-one, and their use as v1b or both v1b and v1a arginine-vasopressin ligand receptors |
| 09/07/2001 | WO2001064666A1 Oxygen-containing heterocyclic compounds |
| 09/07/2001 | WO2001064655A1 2, 4-di(hetero-)arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents |
| 09/07/2001 | WO2001064653A1 Pyrimidine compounds |
| 09/07/2001 | WO2001064631A2 Derives de polyfluoroalkylimidazole et leur utilisation en tant qu'antagonistes des recepteur muscariniques m3 et serotoniques 5-ht4 |
| 09/07/2001 | WO2001064247A2 Method of treating cancer with anti-neurotrophin agents |
| 09/07/2001 | WO2001064236A2 METHODS FOR TREATING FSH RELATED CONDITIONS WITH GnRH ANTAGONISTS |
| 09/07/2001 | WO2001064208A1 Il-8 receptor antagonists |
| 09/07/2001 | WO2001064200A2 Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy |
| 09/07/2001 | WO2001064165A2 Il-8 receptor antagonists |
| 09/07/2001 | WO2001021761A3 Recombinant adenoviral vectors and their utility in the treatment of various types of fibrosis: hepatic, renal, pulmonary, as well as hypertrophic scars |
| 09/07/2001 | WO2001016135A3 Reverse-turn mimetics and methods relating thereto |
| 09/07/2001 | WO2001012812A3 Baff receptor (bcma), an immunoregulatory agent |
| 09/07/2001 | WO2001010383A3 Caspase inhibitors and uses thereof |
| 09/07/2001 | WO2000075107A3 Bradykinin receptor antagonists |
| 09/07/2001 | WO2000047603A9 16-hydroxyestratrienes as selective estrogens |
| 09/07/2001 | CA2401993A1 Human monoclonal antibodies against oxidized ldl receptor and pharmaceutical uses thereof |
| 09/07/2001 | CA2401834A1 Novel imidazotriazinones and the use thereof |
| 09/07/2001 | CA2401697A1 Pyrazole ether derivatives as anti-inflammatory/analgesic agents |
| 09/07/2001 | CA2401659A1 Il-8 receptor antagonists |
| 09/07/2001 | CA2401489A1 Oxygen-containing heterocyclic compounds |
| 09/07/2001 | CA2401453A1 G-proteins coupled receptor related polypeptides |
| 09/07/2001 | CA2401022A1 Methods for treating fsh related conditions with gnrh antagonists |
| 09/07/2001 | CA2400649A1 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors |
| 09/07/2001 | CA2399704A1 Pyrimidine compounds |
| 09/07/2001 | CA2398685A1 2,4-di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents |
| 09/06/2001 | US20010020042 Fluorophenyl-substituted alkenylcarboxylic acid guanidides, process for their preparation, their use as a medicament or diagnostic, and medicament containing them |
| 09/06/2001 | US20010020034 Isothiazole derivatives useful as anticancer agents |
| 09/06/2001 | US20010020021 Metalloprotease inhibitor |
| 09/06/2001 | US20010020013 Polymerase inhibitors |
| 09/06/2001 | US20010020006 Dipeptidyl peptidase; antidiabetic agents |
| 09/06/2001 | US20010019719 Intravesical drug delivery system |
| 09/06/2001 | DE10010067A1 New 2-phenyl-imidazo (5,1-f) (1,2,4) triazin-4-one derivatives, are phosphodiesterase inhibitors useful for treating cardiovascular, cerebrovascular or urogenital disorders |
| 09/05/2001 | EP1130017A2 Azole derivatives and their use as superoxide radical inhibitors |
| 09/05/2001 | EP1129718A2 Therapeutic uses of bactericidal/permeability increasing protein products |
| 09/05/2001 | EP1129711A2 Pinolenic acid against diabetes |
| 09/05/2001 | EP1129351A2 COMPOSITIONS AND METHODS RELATING TO THE PEROXISOMAL PROLIFERATOR ACTIVATED RECEPTOR-$g(a) MEDIATED PATHWAY |
| 09/05/2001 | EP1129350A1 Methods for identifying modulators of bs69 activity |
| 09/05/2001 | EP1129189A2 Human cell surface receptor proteins |
| 09/05/2001 | EP1129089A1 Spiro-indolines as y5 receptor antagonists |
| 09/05/2001 | EP1129078A2 Indazole derivatives with 5-ht2 receptor activity |
| 09/05/2001 | EP1129077A1 Fluorinated 3,4-dihydroquinoline derivatives used as nos inhibitors |
| 09/05/2001 | EP1129076A1 Tetrahydroisoquinoline derivatives as lhrh antagonists |
| 09/05/2001 | EP1129074A2 Antrhranilic acid amides and the use thereof as medicaments |
| 09/05/2001 | EP1129072A2 N-substituted azacycles, their preparation and their use as orl-1 receptor ligands |
| 09/05/2001 | EP1128830A1 Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts |
| 09/05/2001 | EP1128825A1 A new composition |
| 09/05/2001 | EP1128819A1 New controlled release bead, a method of producing the same and multiple unit formulation comprising it |
| 09/05/2001 | EP0832061B1 Benzamide derivatives and their use as vasopressin antagonists |
| 09/05/2001 | EP0699185B1 GUANIDINE DERIVATIVES AS INHIBITORS OF Na+ /H+ EXCHANGE IN CELLS |
| 09/05/2001 | CN1311691A Antithrombotic agent and humanized anti-von willebrand factor monoclonal antibody |
| 09/05/2001 | CN1311682A Pharmaceutical compositions and uses for androst-5-ene-3beta, 17 beta-diol |
| 09/05/2001 | CN1311680A Pyrrolo [2,3d] pyrimidine compositions and their use |
| 09/05/2001 | CN1311674A Antioxidant, antiproliferous compositions, comprising a carnitine and a cerotenoid |
| 09/05/2001 | CN1311671A Peptidyl-prolyl i-(cis)-trans isomerase inhitors and uses thereof |
| 09/05/2001 | CN1311031A Chinese kerbal medicine preparation for curing urinaemia |
| 09/05/2001 | CN1070492C Tetracylic derivatives, process for prepn. of same and use |
| 09/04/2001 | US6285537 Stress-follower circuit configuration |
| 09/04/2001 | US6284774 4-Benzyl piperidine alkylsulfoxide heterocycles and their use as subtype-selective NMDA receptor antagonists |
| 09/04/2001 | US6284734 Nonapeptide |
| 09/04/2001 | US6284515 Signal recognition particle polypeptides and polynucleotides |
| 09/04/2001 | US6284268 Cyclosporin, synergistic |
| 08/30/2001 | WO2001062923A2 Transporters and ion channels |
| 08/30/2001 | WO2001062757A1 Novel compounds |
| 08/30/2001 | WO2001062756A1 Pyridinylimidazoles |
| 08/30/2001 | WO2001062733A1 Ortho-sulfonamido aryl hydroxamic acids, process for their preparation and their use as matrix metalloproteinase inhibitors |
| 08/30/2001 | WO2001062729A1 Novel compounds |
| 08/30/2001 | WO2001062728A1 Novel compounds |
| 08/30/2001 | WO2001062706A1 Aminoadamantane derivatives as therapeutic agents |
| 08/30/2001 | WO2001062705A2 Aminoalcohol derivatives |
| 08/30/2001 | WO2001062292A1 Preventive or therapeutic drugs for fibrosis containing chymase inhibitors as the active ingredient |
| 08/30/2001 | WO2001062263A2 Use of pentosan polysulfate for the manufacture of a medicament for the treatment of male chronic pelvic pain syndrome |
| 08/30/2001 | WO2001062257A2 Bupropion metabolites and methods of their synthesis and use |
| 08/30/2001 | WO2001062236A2 New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent |
| 08/30/2001 | WO2001012195A3 Use of morphine derivatives as medicaments for the treatment of neuropathic problems |
| 08/30/2001 | WO2000040733A9 Human cyclic nucleotide pdes |
| 08/30/2001 | US20010018451 Raloxifene, tamoxifen |
| 08/30/2001 | US20010018447 Il-8 receptor antagonists |
| 08/30/2001 | CA2401113A1 Transporters and ion channels |
| 08/30/2001 | CA2401036A1 Pyridinylimidazoles |
| 08/30/2001 | CA2401013A1 Ortho-sulfonamido aryl hydroxamic acids, process for their preparation and their use as matrix metalloproteinase inhibitors |
| 08/30/2001 | CA2400435A1 Novel compounds |
| 08/30/2001 | CA2400434A1 Novel compounds |
| 08/30/2001 | CA2400293A1 Novel compounds |
| 08/30/2001 | CA2399442A1 New drug combinations |
| 08/30/2001 | CA2368366A1 Medicament for prevention or treatment of fibrosis having chymase inhibitor as effective ingredient |
| 08/29/2001 | EP1127880A2 Phenylacetic acid derivatives substituted by a heterocycle and their use as A-II antagonists and as inhibitors of smooth muscle cell proliferation |
| 08/29/2001 | EP1127131A2 Connective tissue growth factor (ctgf) and methods of use |
| 08/29/2001 | EP1127074A1 Methods for determining whether a compound is capable of inhibiting the interaction of a peptide with rage |
| 08/29/2001 | EP1127071A1 Compounds with growth hormone releasing properties |
| 08/29/2001 | EP1127052A1 Substituted 2-phenylbenzimidazoles, the production thereof and their use |
| 08/29/2001 | EP1126879A1 Gene therapy for regulating smooth muscle cell tone |
| 08/29/2001 | EP1126865A2 Methods and compositions for treating or preventing peripheral neuropathies |